| Hazard Information | Back Directory | [Uses]
SH-BC-893 is an orally active anti-neoplastic sphingolipid analog. SH-BC-893 also protects from ceramide-induced mitochondrial dysfunction and corrects diet-induced obesity. SH-BC-893 can be used for the research of cancer and obesity[1][2]. | [in vivo]
SH-BC-893 (oral; 120 mg/kg; single) robustly and acutely blocks ceramide-induced mitochondrial dysfunction, correcting diet-induced obesity and its metabolic sequelae[1]. | Animal Model: | C57BL/6J mice (Male)[1] | | Dosage: | 120 mg/kg | | Administration: | Oral; single | | Result: | Blocked palmitate- and ceramide-induced mitochondrial fission, preserved mitochondrial function, and prevented ER stress.
Normalized mitochondrial morphology in the livers and brains of HFD-fed mice, improved mitochondrial function in white adipose tissue, and corrected aberrant plasma leptin and adiponectin levels.
Restored normal body weight, glucose disposal, and hepatic lipid levels in mice consuming a HFD.
|
| [References]
[1] Kubiniok, Peter et al. Dynamic Phosphoproteomics Uncovers Signaling Pathways Modulated by Anti-oncogenic Sphingolipid Analogs. Molecular & cellular proteomics : MCP vol. 18,3 (2019): 408-422. DOI:10.1074/mcp.RA118.001053
[2] Jayashankar, Vaishali et al. Drug-like sphingolipid SH-BC-893 opposes ceramide-induced mitochondrial fission and corrects diet-induced obesity. EMBO molecular medicine vol. 13,8 (2021): e13086. DOI:10.15252/emmm.202013086 |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
www.chemicalbook.com/showsupplierproductslist927327/0_en.htm |
|